A Brief Overview on microRNA-based Cancer Screening by Blood Test | Chapter 11 | Research Highlights in Disease and Health Research Vol. 5

 This review item is designed for developing a hide device for feelings cancer where early discovery can save a life. The use of the miRNA as a biomarker is widespread in many mature research findings and microscopic diagnosis, both of that are quite advanced. Numerous miRNAs have happened found expected dysregulated for different types of cancer, in accordance with research on miRNAs and cancer. One technique for weighing the expression of miRNA using microscopic beacon probes is certain-time PCR. miRNA plays an important part in regulating various genes post-transcriptionally by ruling gene verbalization levels. miRNAs are found to regulate stem container differentiation which is main to various tool development. Molecular beacon probes accompanying multiple miRNAs can also be planned to detect diversified disease situations place identified miRNAs exist. Screening extreme-risk populations for conscience cancer is an urgent need, and the method should be able to reach a a lot of people at a cheap.

Author(s) Details:

Bindu Salim,
Nanotech Research Innovation and Incubation Centre, PSG Institute of Advanced Studies, Coimbatore-641004, Tamil Nadu, India.

A. Kandaswamy,
Industrial Research and Development, PSG College of Technology, Coimbatore-641004. Tamil Nadu, India.

M. V. Athira,
Nanotech Research Innovation and Incubation Centre, PSG Institute of Advanced Studies, Coimbatore-641004, Tamil Nadu, India.

Madhulika Vijayakumar,
PSG Institute of Medical Science and Research, Coimbatore-641004, Tamil Nadu, India.

Please see the link here: https://stm.bookpi.org/RHDHR-V5/article/view/10123

Recent Developments in the Laboratory Diagnosis of Tuberculosis | Chapter 12 | Recent Developments in Medicine and Medical Research Vol. 4

 Despite advances in tuberculosis (TB) laboratory diagnosis in the previous 30 years, only a small portion of the world's population has benefited. The World Health Organization (WHO) recommends utilising nucleic acid amplification tests (NAAT) instead of smear microscopy to detect tuberculosis since NAAT can detect TB with greater precision, particularly in patients with paucibacillary disease and HIV-positive individuals. A number of molecular TB detection tests are now being developed and evaluated, some for use in reference laboratories and others for use in primary care and point-of-care settings. In nations with a high TB burden, the number of molecular tests created, manufactured, and deployed has increased, and some are specifically tailored for use in sites close to the patient. In drug susceptibility testing, NAAT with next-generation sequencing may provide faster results than normal phenotypic culture. Furthermore, as with tuberculin skin tests (TST), the results of tests that detect or quantify cytokines released during the inflammatory process in latent tuberculosis infection (LTBI), such as the Interferon-Gamma Release Assay (IGRA), or that quantify IL-6 or other cytokines, are dependent on the prevalence of TB in the tested population. In this research, we look at recent advancements in TB detection assays as well as anti-TB drug resistance.

Author(S) Details

Garcia-Elorriaga Guadalupe
National Medical Center La Raza, CMNR, Mexican Social Security Institute, IMSS, Mexico City, Mexico.

Del Rey-Pineda Guillermo
Federico Gomez Children’s Hospital, Mexico City, México.

View Book:- https://stm.bookpi.org/RDMMR-V4/article/view/4177